Skip Navigation

Cardiovascular Research 2003 58(1):203-212; doi:10.1016/S0008-6363(02)00843-X
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shimizu, T.
Right arrow Articles by Kitabatake, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimizu, T.
Right arrow Articles by Kitabatake, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

VEGF-mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts

Toshihiro Shimizu, Hiroshi Okamoto*, Satoru Chiba, Yutaka Matsui, Takeshi Sugawara, Masatoshi Akino, Jia Nan, Hideki Kumamoto, Hisao Onozuka, Taisei Mikami and Akira Kitabatake

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan

* Corresponding author. Tel.: +81-11-716-1161; fax: +81-11-706-7874. okamotoh{at}hucc.hokudai.ac.jp

Objective: Coronary microcirculation plays an important role in the progression of cardiac remodeling. Among angiogenic factors, it has been reported that angiotensin II may contribute to neovascularization. However, it is unknown whether inhibition of the renin–angiotensin system suppresses angiogenesis, especially within the heart. Our aim was to evaluate the effects of the angiotensin-converting enzyme inhibitor enalapril and the angiotensin II receptor type I blocker valsartan on cardiac microvasculature, function, vascular endothelial growth factor (VEGF) expression, and survival in cardiomyopathic hamsters. Methods: Male cardiomyopathic hamsters (BIO TO2) were administered either a placebo (group C), enalapril (30 mg/kg/day) (group E), or valsartan (40 mg/kg/day) (group V), starting at the age of 6 weeks. This continued until death. Hemodynamic study, histological analysis, and northern blot analysis were performed at 39 weeks. Results: Group V showed significant increases in percent fibrosis, end diastolic pressure, and LV dP/dt min, and significant decreases in percent fractional shortening, LV dP/dt max, capillary density, and the level of mRNA expression of VEGF compared with group C. Group E showed significant increases in percent fractional shortening while the capillary density and level of mRNA expression of VEGF were unchanged. The 300-day survival rate was significantly lower in group V (25.0%) but higher in group E (100%) than that of group C (66.7%). Conclusions: Therapy with valsartan may have adverse effects on survival rate concomitant with the progression of cardiac remodeling owing to impaired VEGF-mediated angiogenesis. Therapy with enalapril has a neutral effect on VEGF-mediated angiogenesis, leading to the suppression of cardiac remodeling and an increase in life expectancy.

KEYWORDS %FS, percent fractional shortening; ACEI, angiotensin-converting enzyme inhibitor; AII, angiotensin II; ARB, angiotensin type I receptor blockade; AST, asparaginate amino transferase; ATI receptor, angiotensin type I receptor; BK, bradykinin; BW, body weight; Cr, creatinine; DAB, 3',3'-diaminobenzidine; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GSA-B4, the lectin Griffonia simplicifolia; HR, heart rate; LV, left ventricular; LV dP/dt max, the maximum rate of rise in left ventricular pressure; LV dP/dt min, the maximum rate of fall in left ventricular pressure; LVDd, left ventricular end-diastolic dimension; LVEDP, left ventricular end-diastolic pressure; LVSP, left ventricular systolic pressure; LVW, left ventricular weight; NO, nitric oxide; PBS, phosphate-buffered saline; PG, prostaglandins; RAS, the renin–angiotensin system; SR, synchrotron radiation; VEGF, vascular endothelial growth factor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. E. Gonzalez, I. M. Seropian, M. L. Krieger, J. Palleiro, M. A. Lopez Verrilli, M. M. Gironacci, S. Cavallero, L. Wilensky, V. H. Tomasi, R. J. Gelpi, et al.
Effect of early versus late AT1 receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H375 - H386.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
H. Kondoh, Y. Sawa, N. Fukushima, G. Matsumiya, S. Miyagawa, S. Kitagawa-Sakakida, Y. Imanishi, N. Kawaguchi, N. Matsuura, and H. Matsuda
Combined Strategy Using Myoblasts and Hepatocyte Growth Factor in Dilated Cardiomyopathic Hamsters
Ann. Thorac. Surg., July 1, 2007; 84(1): 134 - 141.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
D. Ribatti, M. T. Conconi, and G. G. Nussdorfer
Nonclassic Endogenous Novel Regulators of Angiogenesis
Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Rakusan, Z. Chvojkova, P. Oliviero, I. Ostadalova, F. Kolar, C. Chassagne, J.-L. Samuel, and B. Ostadal
ANG II type 1 receptor antagonist irbesartan inhibits coronary angiogenesis stimulated by chronic intermittent hypoxia in neonatal rats
Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1237 - H1244.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Ushio-Fukai
Redox signaling in angiogenesis: Role of NADPH oxidase
Cardiovasc Res, July 15, 2006; 71(2): 226 - 235.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
R. Dechend, V. Homuth, G. Wallukat, D. N. Muller, M. Krause, J. Dudenhausen, H. Haller, and F. C. Luft
Agonistic Antibodies Directed at the Angiotensin II, AT1 Receptor in Preeclampsia
Reproductive Sciences, February 1, 2006; 13(2): 79 - 86.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
H. Kondoh, Y. Sawa, S. Miyagawa, S. Sakakida-Kitagawa, I. A. Memon, N. Kawaguchi, N. Matsuura, T. Shimizu, T. Okano, and H. Matsuda
Longer preservation of cardiac performance by sheet-shaped myoblast implantation in dilated cardiomyopathic hamsters
Cardiovasc Res, February 1, 2006; 69(2): 466 - 475.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. Xu, K. Nagata, K. Obata, S. Ichihara, H. Izawa, A. Noda, T. Nagasaka, M. Iwase, T. Naoe, T. Murohara, et al.
Nicorandil Promotes Myocardial Capillary and Arteriolar Growth in the Failing Heart of Dahl Salt-Sensitive Hypertensive Rats
Hypertension, October 1, 2005; 46(4): 719 - 724.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
H. Kondoh, Y. Sawa, N. Fukushima, G. Matsumiya, S. Miyagawa, S. Kitagawa-Sakakida, I. A. Memon, N. Kawaguchi, N. Matsuura, and H. Matsuda
Reorganization of cytoskeletal proteins and prolonged life expectancy caused by hepatocyte growth factor in a hamster model of late-phase dilated cardiomyopathy
J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 295 - 302.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. M. Davison, V. Homuth, A. Jeyabalan, K. P. Conrad, S. A. Karumanchi, S. Quaggin, R. Dechend, and F. C. Luft
New Aspects in the Pathophysiology of Preeclampsia
J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2440 - 2448.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
F. C. Luft
Pieces of the preeclampsia puzzle
Nephrol. Dial. Transplant., November 1, 2003; 18(11): 2209 - 2210.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.